Risk factors for the development of haemorrhagic anovulatory follicles in the mare.
Haemorrhage into the dominant follicle during the reproductive season is a subtle but definitive cause of infertility in the mare population. This condition however can be of high relevance for an individual in which its incidence is abnormally high. Little is known about the nature and factors affecting the incidence of haemorrhagic anovulatory follicles (HAFs) in the mare. The objectives of the study were to define and characterize the ultrasonographic development and incidence of HAFs and to investigate possible risk factors influencing its occurrence. Detailed reproductive and ultrasound records of seven mares studied during their entire reproductive lives (>10 years and 612 oestrous cycles) were analysed retrospectively and computed into a statistical mixed model. Of all animal studied, two mares were found to have an unusually high incidence of HAFs of approximately 25%. Time of season and use of induction treatments (Cloprostenol) were found to influence its incidence. It appears that early-enhanced stimulatory effect of LH on an ovary with the presence of small and immature follicles might increase the risk of ovulatory failure of those follicles later in the cycle. Mares during the months of highest follicular activity (May to August) and after treatment with hormones to induce oestrus and ovulation are at greater risk to develop HAFs. The potential relevance of this study is two folds: clinical relevance for the practitioner to better understand this condition and so improve reproductive management of mares with abnormally high incidence; and to provide useful insights for researchers willing to further investigate the nature of this phenomenon.
Cuervo-Arango
J
J
Department of Veterinary Clinical Sciences, Royal Veterinary College, University of London, North Mymms, Hertfordshire, UK. copicuervo@hotmail.com
Newcombe
J R
JR
D000818:Animals; D000858:Anovulation / Q000209:etiology / Q000662:veterinary; D003008:Cloprostenol / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006470:Hemorrhage / Q000453:epidemiology / Q000209:etiology / Q000662:veterinary*; D006734:Horse Diseases / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000209:etiology*; D006736:Horses; D007247:Infertility, Female / Q000209:etiology / Q000662:veterinary; D008186:Luteolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D010049:Ovarian Diseases / Q000453:epidemiology / Q000209:etiology / Q000662:veterinary*; D006080:Ovarian Follicle / Q000000981:diagnostic imaging; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods / Q000662:veterinary; D012189:Retrospective Studies; D012307:Risk Factors; D012621:Seasons; D014463:Ultrasonography
D008186:Luteolytic Agents; D003008:Cloprostenol